Mirum Pharmaceuticals to Acquire Bluejay Therapeutics, Strengthening Rare Disease Portfolio

Shots: Mirum Pharmaceuticals has entered into an agreement to acquire Bluejay Therapeutics, gaining global rights to brelovitug with Breakthrough Therapy and PRIME designations, and expanding Mirum’s rare liver disease portfolio As per the deal, Mirum will acquire all Bluejay shares for $250M in cash and $370M in Mirum stock, plus up to $200M in sales-based…

ByDipanshu DixitDecember 9, 2025

NEWS

Viatris Enters Agreement to Monetize Equity Stake in Biocon Biologics for ~$815M

Shots: Viatris has signed definitive agreements to sell its Biocon Biologics stake to Biocon for ~$815M Under the agreements, Viatris will sell its Biocon Biologics stake to Biocon for $400M in cash and $415M in Biocon shares, to be listed on NSE with a six-month lock-up. As part of the agreement, the biosimilar non-compete restrictions…

ByDipanshu DixitDecember 8, 2025

NEWS

Gilead Acquires TREX1 Program from Sprint Bioscience for ~$414M

Shots: Sprint Bioscience has reported the sale of its TREX1 cancer program to Gilead Sciences As per the Deal, Sprint Bioscience will receive $14M upfront and up to $400M in clinical, regulatory, and commercial milestones TREX1 program has demonstrated notable potential in the pre-clinical stage Ref: Sprint Bioscience | Image: Gilead & Sprint Bioscience | Press…

ByRidhi RastogiNovember 25, 2025

NEWS

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Shots: Sandoz agreed to acquire Just-Evotec Biologics EU SAS in Toulouse , including its manufacturing site to expand in-house continuous manufacturing for biosimilars, supporting its strategy to capture a projected ~$300B biosimilars market over the next decade Sandoz will buy 100% of Just-Evotec Biologics SAS and secure a perpetual license for its continuous manufacturing platform…

ByDipanshu DixitNovember 5, 2025

NEWS

Ipsen Acquires ImCheck Therapeutics, Enhancing its Oncology Leadership and Strengthening its Pipeline

Shots: Ipsen enters into a definitive share purchase agreement with ImCheck Therapeutics to acquire later's all issued and outstanding shares, including lead candidate ICT01, a P-I/II therapy for 1L AML pts ineligible for intensive CT As per the deal, shareholders of ImCheck Therapeutics will receive €350M ($406.62M) in closing purchase price, with additional deferred payments…

ByDipanshu DixitOctober 23, 2025

NEWS

Blackstone and TPG Acquire Hologic for ~ $18.3B

Shots: Hologic has agreed to be acquired by Blackstone and TPG for up to $79 per share, valuing the deal at up to $18.3B. The deal is expected to close in H1'26 As per the deal, Blackstone and TPG will acquire all Hologic shares for $76 per share in cash plus a non-tradable CVR worth…

ByDipanshu DixitOctober 21, 2025

NEWS

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Shots: AbbVie has entered into a definitive agreement to acquire Capstan Therapeutics, including its P-I CPTX2309 and proprietary tLNP platform for in vivo RNA delivery to treat B-cell-mediated autoimmune diseases As per the deal, Capstan will receive up to $2.1B in cash, pending customary closing conditions and regulatory approvals CPTX2309 is a tLNP delivering mRNA…

ByDipanshu DixitJuly 1, 2025

NEWS

Torrent Pharma to Acquire a Controlling Stake in JB Chemicals & Pharmaceuticals from KKR for ~$3B

Shots: Torrent Pharma acquired a controlling stake in JB Pharma from KKR in a strategic move to build a diversified healthcare platform As per the deal, KKR will receive INR 25,689 crore (~$3B) Equity Valuation on a fully diluted basis. Torrent will acquire a 46.39% stake in JB Pharma for ₹11,917 crore (~$1.39B) at INR 1,600…

ByDipanshu DixitJuly 1, 2025

Mirum Pharmaceuticals to Acquire Bluejay Therapeutics, Strengthening Rare Disease Portfolio

Viatris Enters Agreement to Monetize Equity Stake in Biocon Biologics for ~$815M

Gilead Acquires TREX1 Program from Sprint Bioscience for ~$414M

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Ipsen Acquires ImCheck Therapeutics, Enhancing its Oncology Leadership and Strengthening its Pipeline

Blackstone and TPG Acquire Hologic for ~ $18.3B

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Torrent Pharma to Acquire a Controlling Stake in JB Chemicals & Pharmaceuticals from KKR for ~$3B

Contact US

OUR INFORMATION

FOLLOW US